Precision Biosciences (DTIL) Net Cash Flow (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Net Cash Flow of -$11.3 million for Q1 2026, down 30.27% year-over-year from -$16.2 million in Q1 2025, and down 117.15% quarter-over-quarter from $65.9 million in Q4 2025.
Precision Biosciences (DTIL) Net Cash Flow (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Net Cash Flow for 9 consecutive years, with -$11.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 30.27% year-over-year to -$11.3 million; the TTM figure through Mar 2026 stood at $26.1 million (up 168.62% YoY), while the FY2025 annual figure was $28.7 million, up 449.39% from the prior year.
- Net Cash Flow declined to -$11.3 million in Q1 2026 per DTIL's latest filing, from $65.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $67.9 million in Q2 2022 and bottomed at -$31.4 million in Q1 2023.
- Historically, Net Cash Flow has averaged -$1.0 million across 5 years, with a median of -$12.9 million in 2024.
- On a YoY basis, Net Cash Flow climbed as much as 612.76% in 2025 and fell as far as 506.06% in 2025.
- Precision Biosciences' Net Cash Flow stood at -$22.5 million in 2022, then surged by 75.29% to -$5.6 million in 2023, then tumbled by 131.59% to -$12.9 million in 2024, then soared by 612.76% to $65.9 million in 2025, then tumbled by 117.15% to -$11.3 million in 2026.
- Business Quant data shows DTIL's Net Cash Flow at -$11.3 million in Q1 2026, $65.9 million in Q4 2025, and -$13.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | -13.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.44 Mn |
| Jun 30, 2026 | -13.44 Mn |
| Mar 31, 2026 | -11.31 Mn |
| Mar 31, 2026 | -11.31 Mn |
| Dec 31, 2025 | 65.94 Mn |
| Dec 31, 2025 | 65.94 Mn |
| Sep 30, 2025 | -13.59 Mn |
| Sep 30, 2025 | -13.59 Mn |
| Jun 30, 2025 | -14.98 Mn |
| Jun 30, 2025 | -14.98 Mn |
| Mar 31, 2025 | -8.68 Mn |
| Mar 31, 2025 | -8.68 Mn |
| Dec 31, 2024 | -12.86 Mn |
| Dec 31, 2024 | -12.86 Mn |
| Sep 30, 2024 | -2.24 Mn |
| Sep 30, 2024 | -2.24 Mn |
| Jun 30, 2024 | -14.20 Mn |
| Jun 30, 2024 | -14.20 Mn |
| Mar 31, 2024 | 21.09 Mn |
| Mar 31, 2024 | 21.09 Mn |